Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This case report highlights a 73-year-old man developing rosacea-like dermatitis after taking icotinib hydrochloride for NSCLC, suggesting awareness of this side effect is important for clinicians.

This study reported significant transcriptomic changes in keratinocyte and immune cell populations in a mouse model with EGFR-deficient epidermis, suggesting possible targets for mitigating adverse skin events in EGFR-targeted cancer therapy.

In this case report, researchers observed a Slovakian neonate with a rare EGFR genetic mutation who presented with severe neonatal dermatoses, ichthyosis, and multisystem complications, emphasizing the significance of genetic diagnosis for such complex conditions.

EGFR is essential for organized skin nerve growth and branching.

EGFR-targeted cancer therapy can cause skin issues starting at hair follicles, leading to inflammation.

This study discusses two cases of acneiform skin eruptions associated with the use of the EGFR inhibitor ZD1839 in prostate cancer treatment, emphasizing the need for dermatologists to be aware of potential skin reactions.

Blocking EGFR in mice causes hair loss and skin changes.

This article explores potential mechanisms of acneiform skin eruptions linked to EGFR inhibition in cancer patients, focusing on EGFR's role in controlling IL-1-dependent inflammation at hair follicles, but reports no clinical results.

This study examined the FDA Adverse Events Reporting System and found new dermatologic adverse events associated with EGFR-TKIs in non-small cell lung cancer patients, such as specific skin, nail, and hair issues, that aren't currently listed on drug labels.

This study reported that the most common skin side effect of epidermal growth factor receptor inhibitors was a papulopustular rash, treatable with symptom-targeted therapies, while drug suspension was rarely needed.

This paper discusses the role of epidermal growth factor receptor blockade in altering skin and hair growth, highlighting hair growth stimulation as a potential side effect of cancer therapy; it reports no new experimental results.

Skin problems like acne, dry skin, and nail and hair changes are common in patients taking EGFR inhibitors.

This review observes that trichomegaly, a newly described side effect of EGFR inhibitors causing excessive eyelash and scalp hair growth, persists in some patients whose tumors respond positively to the therapy.

This report describes a rare case of a non-small-cell lung cancer patient experiencing hair changes after prolonged gefitinib treatment, potentially linked to EGFR inhibition, with limited understanding of its cause.

This study found that histopathologic features of erythematous papulopustular eruption due to EGFR inhibitors vary with eruption severity and differ between cetuximab and erlotinib treatments.

This review highlights that chemotherapy-induced skin toxicities from EGFR inhibitors in breast cancer treatment can significantly impact patient quality of life and treatment adherence, emphasizing the importance of proactive management and patient discussions.

This study found that neutrophil-rich hair follicle inflammation caused by a monoclonal antibody targeting murine EGFR in mice involved TNFα and interleukin-1, suggesting these cytokines play a role in EGFR antibody-induced rashes in cancer patients.

This study suggests that EREG, released from ORS cells, may promote hair growth by activating specific receptors and modulating ROS generation, offering a potential new treatment for hair loss.

This study reported that EGFR inhibitor therapy in lung and head/neck cancer patients was associated with acneiform eruptions and severe skin dryness, which rarely necessitate discontinuation of treatment and can be managed symptomatically.

This study identified a novel microscopic "arrow sign" in hair root sheaths of patients on EGFR inhibitors, potentially aiding in diagnosing related hair changes and differentiating from fungal infections.

This study found that epidermal growth factor receptor inhibitors can induce erosive pustular dermatosis of the scalp, typically appearing sooner and affecting the scalp more extensively compared to other triggers.

This study reports that blocking the epidermal growth factor receptor in cancer treatments can lead to changes in hair growth and create a "wavy" hair phenotype in some patients.

This case report describes a patient who developed PRIDE syndrome-associated skin issues, including a pruritic papulopustular rash and alopecia, after starting treatment with the EGFR inhibitor erlotinib.

This study using a genetic mouse model found that S. aureus-driven dysbiosis sustains inflammatory skin side effects from EGFR inhibitors, suggesting prophylactic antibiotic treatment may reduce rash severity without fixing barrier defects.

This study found that in mice, EGFR activation suppresses mitotic regulators like Rcc2 and Stathmin 1, facilitating the transition to catagen in hair follicles.

This review discusses the mechanisms and pathways of FGFR signalling and its roles in development, disorders, and therapeutic targeting, but reports no new clinical results.

This report discusses two cases where patients continued EGFR inhibitor therapy while receiving topical treatments for SDRIFE, highlighting the importance of dermatologists in managing such cutaneous adverse events without stopping cancer treatment.

This manuscript describes two case reports of preterm newborns with a rare homozygous mutation in the epidermal growth factor receptor, leading to severe health issues and early mortality despite supportive care.

This paper describes the PRIDE syndrome associated with epidermal growth factor receptor inhibitors but reports no new clinical results.